Corcept Therapeutics price target raised to $115 from $80 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $115 from $80 and keeps a Buy rating on the shares. The firm says relacorilant “could be a major growth driver” for the company. Corcept revenue could see a boost with the upcoming expected approval of the selective cortisol modulator, relacorilant, the analyst tells investors in a research note. In the event relacorilant is adopted in the difficult-to-control diabetes patient population, H.C. Wainwright sees significant upside to its current estimates.